Multicenter, randomized, open-label non-inferiority trial, comparing two antibiotic therapy periods (3 versus 7 days) in patients with mild leptospirosis and seen at the hospital in 5 French overseas departments (Martinique, Guadeloupe, French Guiana, Reunion, Mayotte)
- Registry ID
- 2024-518027-30-00
- Source registry
- CTIS
- Status
- Authorised
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- CHU De Martinique
- Enrollment
- 304
- Last update
- 2026-08-13
Conditions
- leptospirosis
- Diseases [C] - Bacterial Infections and Mycoses [C01]
Primary outcomes
Treatment failure at 7 days from the beginning of antibiotic therapy as defined by occurrence of a complication described in the end points, Hemodynamic failure with onset of septic shock defined by persisting hypotension requiring vasopressor amines to maintain mean arterial pressure ≥65 mm Hg and blood lactates >2 mmol/L despite adequate volume resuscitation, Hematologic failure with hemoglobin <7 g / dL requiring red blood cell transfusion or platelets < 20 G / L requiring platelet transfusion, Ventilatory failure defined by PaO2 / Fi O2 ratio <300 mmHg or resort to mechanical ventilation, Renal failure defined by serum creatinine > 301 μmol / L or resort to renal dialysis, Hepatic failure defined by total bilirubinemia> 101 μmol / L, Heart failure (eg: ECG anomalies, myocarditis, cardiogenic shock), Neurologic affection such as meningitis, encephalitis, intracerebral hemorragia, stroke, Ocular symptoms such as uveitis, Hemoptysis, lesional pulmonary oedema for pulmonary affection, Hemorrhagic syndrome, Treatment failure at 7 days from the beginning of antibiotic therapy, as defined by continued fever (body temperature >38°C) 5 days after the start of antibiotic therapy, or fever reappearance (body temperature >38°C) observed 24 hours after initial apyrexia (body temperature <38°C). Both cases exclude fever due to a cause not attributable to leptospirosis infection., Treatment failure at 7 days from the beginning of antibiotic therapy, as defined by death
Locations
Related clinical trials
- A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
- Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)
- Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international phase III, double-blind, placebo-controlled, randomized trial - the HAP-DEX study
- A Randomized, Multicenter, Single-Blind, Parallel-Group Phase III Non-Inferiority Trial Comparing the Efficacy and Tolerability of a Fixed-Dose Combination of Metronidazole, Bismuth Oxide and Tetracycline HCl to Standard Concomitant Non-Bismuth Quadruple Therapy for First-Line Eradication of Helicobacter pylori in Adults.
- Adjunctive Hyperbaric Oxygen Treatment for Patients with Necrotizing Soft-Tissue Infection (HOT-NSTI trial)
- LOVIT-ARDS - A Multicentre Concealed‐Allocation Parallel‐Group Blinded Randomized Controlled Trial to Ascertain the Effect of High‐Dose Intravenous Vitamin C Compared to Placebo on Mortality or Persistent Organ Dysfunction at 28 Days in Septic ARDS Patients
View on source registry